Related Experiment Video
Updated: May 5, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
[Severe COVID: A challenge for rheumatologists]
Miriam Berenice Bernal-Enriquez1
1Instituto Mexicano del Seguro Social, Hospital General Regional No. 1, Servicio de Reumatología. Ciudad Obregón, Sonora, México.
Insights
Severe COVID-19 and rheumatologic diseases during the pandemic highlighted management gaps. Further research is needed on immunosuppressants, thrombocytopenia, and fatal outcomes in rheumatic patients.
Area of Science:
- Immunology
- Rheumatology
- Infectious Diseases
Abstract:
The pandemic was a dark time, during which severe COVID and rheumatologic diseases revealed a gap in management. The lack of in-depth analysis on the effects of immunosuppressants on the immune response to SARS-CoV-2 leaves unanswered questions. With small sample sizes and uncertain results, it is urgent to revisit previous databases with the aim of conducting more robust, long-term studies to elucidate how thrombocytopenia and immunosuppressive management influence fatal outcomes in rheumatic patients. Are we ignoring the obvious?
Related Concept Videos
Pericarditis I: Introduction
Pericarditis III: Medical Management
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management

